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Background: The roles that CD16+ monocyte subset plays in T-cell activation and B-cell 
response have not been well studied in systemic lupus erythematosus (SLE).
Objective: The present study aimed to investigate the distribution of CD16+ monocyte 
subsets in SLE and explore their possible roles in T-cell activation and B-cell differentiation.
Methods: The frequencies of monocyte subsets in the peripheral blood of healthy con-
trols (HCs) and patients with SLE were determined by flow cytometry. Monocyte subsets 
were sorted and cocultured with CD4+ T cells and CD19+ B cells. Then, T and B cells 
were collected for different subset detection, while the supernatants were collected 
for immunoglobulin G, IgA, and IgM or interferon-γ and interleukin-17A detection by 
enzyme-linked immunosorbent assay.
results: Our results showed that CD16+ monocytes exhibited a proinflammatory 
phenotype with elevated CD80, CD86, HLA-DR, and CX3CR1 expression on the cell 
surface. It’s further demonstrated that CD16+ monocytes from patients and HCs shared 
different cell-surface marker profiles. The CD16+ subset was enriched in SLE and had an 
exacerbated capacity to promote CD4+ T cell polarization into a Th17 phenotype. Also, 
CD16+ monocytes had enhanced impacts on CD19+ B cells to differentiate into plasma 
B cells and regulatory B cells with more Ig production.
conclusion: This study demonstrated that CD16+ monocytes, characterized by differ-
ent cell-surface marker profiles, were enriched and played a critical role in driving the 
pathogenic T- and B-cell responses in patients with SLE.
Keywords: systemic lupus erythematosus, cD16+ monocytes, expansion, T cell activation, B cell response
inTrODUcTiOn
Systemic lupus erythematosus (SLE) is a chronic autoimmune disease with multiorgan damage 
characterized by immunological abnormalities that include deficient innate immune response 
and aberrant activation of autoreactive T and B cells, with subsequent production of pathogenic 
autoantibodies against cell nuclear components and resultant end-organ injury (1–4). Functional 
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abnormalities in peripheral blood monocytes play a significant 
role in the pathogenesis of SLE, contributing to both aberrant 
T-cell activation and B-cell tolerance (2).
CD16 (FcγRIII) is one of the Fc receptors for immunoglobu-
lin G (IgG) (FcγRs) (5). It is an activating FcγR that transmits 
activation signals through an immune-receptor tyrosine-based 
activation motif contained in its cytoplasmic region and medi-
ates endocytosis and phagocytosis of immune complexes, 
including antibody-coated microorganisms (6). In both mice 
and humans, blood monocyte subsets exhibit differential 
surface expression of various FcγRs. For the past two decades, 
CD16 distinguishes human monocytes into two major subsets 
(CD16+ and CD16− subsets). Subsequently, the third distinct 
monocyte subset driven from CD16+ monocytes was described, 
which was defined as relatively higher levels of CD14 coupled 
with lower CD16 expression. Therefore, human peripheral 
monocytes could be categorized into three subsets: the non-
classical monocytes (NCM, CD14+CD16++), the intermediate 
monocytes (IM, CD14++CD16+), and the classical monocytes 
(CM, CD14++CD16−). NCM and IM are collectively addressed as 
CD16+ monocytes (7, 8).
CD16+ monocytes exhibit low levels of CCR2, the chemokine 
receptor of CCL2 also known as monocyte chemoattractant 
protein 1, and high levels of CX3CR1, known as the fracalkine 
(CX3CL1) receptor (7, 9). Gene expression reveals that non-
classical and intermediate subsets are more closely related 
(10,  11), which is further supported by separate microarray 
study performed with rhesus monkeys that possess homologous 
monocyte subpopulations (12). CD16+ monocytes are considered 
to be pro-inflammatory, as they are better than CD16− mono-
cytes at producing the cytokines-tumor necrosis factor (TNF)-α, 
interleukin (IL)-6, and IL-10 in response to microbial-associated 
molecular patterns (13–15). The results accumulated over the past 
decades suggest that CD16+ subset is expanded in many different 
types of diseases, mostly under infection or inflammatory condi-
tions (16–18). Some studies on monocyte subpopulations were 
performed in patients with SLE. Monocyte subsets exhibited no 
difference in expression of Mer tyrosine kinase between patients 
with SLE and normal controls (19), and IM have modulatory 
effects on CM (20). Mukherjee et al. showed that non-classical 
inflammatory monocytes increased in patients with SLE (21). 
Mikołajczyk et al. suggested that CD14dimCD16+ monocytes are 
associated with subclinical atherosclerosis in SLE (22).
Despite being the main driver of autoimmune diseases, the 
adaptive immune responses are strongly affected by innate 
immune cells. On the one hand, human peripheral blood 
monocytes are shown to act as antigen-processing cells (APCs) 
to activate T cells and secrete cytokines that shape T-cell differ-
entiation in inflammatory diseases, such as rheumatoid arthritis 
and thrombocytopenia (23, 24). On the other hand, monocytes, 
which are generally regarded as precursors of tissue macrophages 
and dendritic cells (DCs) (25), can functionally promote B-cell 
differentiation and antibody secretion in patients with SLE (26, 
27). A substantial literature is available on rats demonstrating the 
critical contribution of monocytes to autoreactive T-cell response 
and B-cell tolerance (28–31). Furthermore, therapies targeting 
monocyte-derived cytokines, such as TNFα, IL-6, or aberrant 
B-cell activation, have been successfully put into clinical practice, 
resulting in dramatically improved clinical outcomes in a number 
of autoimmune diseases (32–34).
To date, the specific roles of monocyte subsets have not been 
fully characterized with regards to T-cell activation and B-cell 
differentiation in SLE. In the present study, the flow cytometry 
analysis was first performed to compare the distribution of each 
subset between healthy individuals and patients with SLE. The 
expression of several cell-surface markers on each monocyte 
subset was also compared, including costimulatory receptors 
(CD80 and CD86), major histocompatibility complex (MHC) 
class II (HLA-DR), scavenger receptor (CD163), and chemokine 
receptors (CCR5, CX3CR1) from patients and healthy controls 
(HCs). Also, the role of monocyte subsets in the polarization 
of Th subsets was explored in patients with SLE. Furthermore, 
the study also investigated the capacity of SLE monocyte sub-
sets in B-cell activation and differentiation. Understanding of 
the mechanisms underlying monocyte subset-mediated T-cell 
 activation and B-cell responses in SLE might disclose novel 
therapeutic targets to treat this disease.
MaTerials anD MeThODs
Patients and controls
Sixty-two patients with SLE and 35 HCs were enrolled at the 
Department of Rheumatology, Peking University People’s 
Hospital, China, and blood samples were obtained from these 
subjects. All of the enrolled patients fulfilled at least four of 
the 2010 American College of Rheumatology revised criteria 
for SLE (35). Demographic, clinical, and laboratory data 
obtained from the medical records of the patients included 
age, sex, disease duration, blood cell counts, 24-h proteinuria 
excretion, anti-double-strand DNA (anti-dsDNA) antibody, 
anti-nucleosome antibody (AnuA), anti-Sm antibody, anti-
SSA antibody, anti-SSB antibody, complement component 
3 (C3), complement component 4 (C4), IgG, IgM, IgA, and 
erythrocyte sedimentation rate (ESR). Anti-dsDNA antibody, 
24-h proteinuria excretion, C3, and C4 levels were used to pre-
dict SLE disease activity. All participants signed the informed 
consents to donate their blood samples and de-identified clini-
cal information for research. The study was approved by the 
Institutional Medical Ethics Review Board of Peking University 
People’s Hospital.
cell staining and Flow cytometric 
analysis
Monocyte subsets were detected in freshly collected blood from 
HC and SLE patients by flow cytometry using the following 
antibodies: fluorescein isothiocyanate (FITC) anti-human CD14 
(Biolegend, San Diego, CA, USA, catalog: 325604), allophyco-
cyanin (APC) anti-human CD16 (Biolegend, clone:3G8, catalog: 
302012), Brilliant Violet 421 anti-human CD80 (Biolegend, cata-
log: 305221), Brilliant Violet 510 anti-human CD86 (Biolegend, 
catalog: 305431), PerCP/Cy5.5 anti-human CD163 (Biolegend, 
catalog: 333608), phycoerythrin (PE)/Dazzle 594 anti-human 
HLA-DR (Biolegend, catalog: 307653), AF700 anti-human CCR5 
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(Biolegend, catalog: 359116), and PE/Cyanine 7 anti-human 
CX3CR1 (Biolegend, catalog: 347612).
T cell subsets were detected after cocultured with monocytes 
using the following antibodies: PE-CF594 anti-human CD4 
(BD Biosciences, San Diego, CA, USA, catalog: 562281), FITC 
anti-human interferon (IFN)-γ (Biolegend, catalog: 502506), 
PE anti-human IL-4 (eBioscience, San Diego, CA, USA, catalog: 
12-7049-42), APC anti-human IL-17A (eBioscience, catalog: 
17-7179-42), and AF 647 anti-human Foxp 3 (Biolegend, catalog: 
320114) Abs.
B cell subsets were detected after cocultured with monocytes 
using the following antibodies: APC-Cyanine 7 anti-human CD19 
(Biolegend, catalog: 302218), FITC anti-human IgD (Biolegend, 
catalog: 348206), PE anti-human CD24 (eBioscience, catalog: 
12-0247-42), PE-Cyanine 7 anti-human CD20 (eBioscience, 
catalog: 25-0209-42), and APC anti-human CD27 (eBioscience, 
catalog: 17-0279-42) mAbs were used.
Gating of the single cells in a forward scatter (FSC)-A and 
FSC-H plot and settings of gates for detecting monocyte subsets 
were shown in Figure 1A. Data were analyzed with FlowJo vX0.7 
(Becton Dickinson).
cell isolation
Venous blood samples (12 mL) were obtained from all subjects. 
Human peripheral blood mononuclear cells were isolated from 
the blood of healthy individuals and patients with SLE using a 
Ficoll gradient centrifugation protocol. Monocyte subsets were 
purified by flow cytometry (BD FACSAria II) based on CD14 and 
CD16 staining. B and T cells were also isolated by flow cytometry. 
Figure S1 in Supplementary Material demonstrates the gating 
strategies about the enrichment and purification of monocyte 
subsets, B cells, and T cells during cell sorting. Sorted cells were 
further assessed by flow cytometric analysis with purity >95, >95, 
and >95% for monocyte subsets, B cells, and T cells, respectively 
(Figure S2 in Supplementary Material).
cell coculture
Fresh SLE blood or healthy control buffy coat samples from 
blood bank were collected for cell coculture assays. The 
monocytes were incubated in RPMI 1640 supplemented with 
10% heat-inactivated fetal calf serum, 100  U/mL penicil-
lin, and 100  μg/mL streptomycin. To evaluate the effects of 
monocyte subsets on T-cell activation, each monocyte subset 
was cocultured with autologous CD4+ T cells (ratio 1:5) in 
the presence of anti-CD3 (1  μg/mL) (eBioscience, catalog: 
16-0037) and anti-CD 28 (1  μg/mL) (eBioscience, catalog: 
16-0289) antibodies (36) and macrophage colony-stimulating 
factor (M-CSF) (50 ng/mL) (Peprotech, Rocky Hill, CT, USA, 
catalog: 300-35). After 5 days, T cells were stimulated for 5 h 
with phorbol 12-myristate 13-acetate (PMA) (50  ng/mL), 
ionomycin (1 μg/mL), and brefeldin A (BFA) (10 μg/mL) (Lian 
ke, Hanzhou, China, catalog: CS0001, CS0002, and CS0003). 
Then, T cells were assessed by staining with anti-IFN-γ (Th1), 
anti-IL-4 (Th2), and anti-17A (Th17) antibodies. Regulatory 
T cells (Treg, Foxp3+CD4+) were monitored by intracellular 
anti-Foxp3 staining. Coculture supernatants were collected for 
IFN-γ and IL-17A measurement.
To explore the roles of monocyte subsets on B-cell response, 
each monocyte subset was cocultured with CD19+ B cells from 
the same donors (ratio 1:2.5) in the presence of anti-CD40 
antibody (37) (3  μg/mL) (eBioscience, catalog:16-0409) and 
M-CSF (50  ng/mL) (Peprotech, catalog: 300-35) for 3  days, 
after which B cells were assessed for the following subpopula-
tions: memory B cells (MBs, CD19+IgD−CD27+), plasma B 
cells (PBs, CD19+CD20−CD27+), and regulatory B cells (Bregs, 
CD19+CD24+CD27+). Coculture supernatants were also har-
vested for Ig measurement.
T-cell Proliferation assay
For labeling isolated T cells, the cells were incubated for 10 min 
at 37°C in 5 mM carboxyfluorescein succinimidyl ester (CFSE) 
(Invitrogen, Carlsbad, CA, USA, catalog: C34554) in phosphate-
buffered saline/0.1% bovine serum albumin (BSA/0.1% PBS). 
Labeling was stopped by adding five volumes of ice-cold RPMI 
1640 to the cells. The cells were washed three times before use. 
Labeled T cells were cocultured with each monocyte subset for 
60 h, as described above. T-cell proliferation was defined as CFSE 
low population indicative of cell division as detected by flow 
cytometry.
enzyme-linked immunosorbent assay
Commercially available enzyme-linked immunosorbent assay 
(ELISA) kits used for measuring IFN-γ, IL-17A, or Ig levels in 
the supernatants were as follows: IFN-γ ELISA kit from R&D 
systems (Minneapolis, MN, USA, catalog: DY285); IL-17A 
ELISA kit from Neobioscience Technology Co., Ltd. (Shenzhen, 
China, catalog: EHC 170); and IgG, IgA, and IgM ELISA kits from 
eBioscience (San Diego, CA, USA, catalog: 88-50550, 88-50600, 
and 88-50620).
statistical analysis
All values were expressed as means ±  SD. Data were analyzed 
for significance using the Statistical Package for Social Sciences 
version 23.0 (SPSS, Chicago, IL, USA) by non-parametric paired 
t test and Mann–Whitney U test. Spearman’s correlation coef-
ficient (r) was applied to determine the correlation between two 
numerical data. A P-value <0.05 was considered statistically 
significant.
resUlTs
cD16+ Monocyte subset Demonstrated 
Different Phenotypes from cD16− cM
Human peripheral blood monocytes could be categorized into 
CD16+ monocytes and CD16− monocytes based on differential 
CD16 expression. The expression of several surface markers, 
including costimulatory receptors (CD80 and CD86), MHC 
class II (HLA-DR), scavenger receptor (CD163), and chemokine 
receptors (CCR5and CX3CR1), was analyzed to determine the 
phenotypic difference between CD16+ monocyte subset and 
CD16− CM in HC donors.
CD16+ monocyte subset demonstrated higher expression 
of CD80, CD86, and HLA-DR compared with CD16− CM in 
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FigUre 1 | cD16+ monocytes exhibited different cell-surface marker expression compared with cD16− monocytes. All samples were collected from 
fresh blood. (a) Representative dot plots in peripheral blood mononuclear cells showed the gating strategy used based on CD14 and CD16 expression. CD16+ 
monocytes could be divided into NCM and IM. (B) CD16+ and CD16− monocyte subsets showed distinctive patterns of cell-surface receptor expression in HCs. 
NCM, non-classical monocytes; IM, intermediate monocytes; CM, classical monocytes. Data were expressed as mean ± SD and analyzed by non-parametric paired 
t test. **P < 0.01, ***P < 0.001; NS, no significance.
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A B
FigUre 2 | cD16+ monocytes as well as their subsets (ncM and iM) were expanded in patients with sle. All samples were collected from fresh blood. 
(a) Representative flow charts showed the percentage of NCM, IM, and CM from a patient with SLE and a healthy control (HC). (B) Frequencies of NCM, IM, CM, 
and CD16+ subset were compared between 62 patients with SLE and 35 age-matched HCs. NCM, non-classical monocytes (CD14+CD16++); IM, intermediate 
monocytes (CD14++CD16+); CM, classical monocytes (CD14++CD16−). Data were expressed as mean ± SD and analyzed by Mann–Whitney U test. *P < 0.05, 
***P < 0.001; NS, no significance.
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control donors (P <  0.001). No difference in CD163 expres-
sion was detected between CD16+ and CD16− monocytes 
(P > 0.05). CCR5 expression was significantly lower in CD16+ 
subset compared with CD16− monocytes (P < 0.01). Also, the 
chemokine receptor CX3CR1 was significantly more expressed 
on CD16+ monocytes than on CD16− monocytes (P < 0.001) 
(Figure 1B).
cD16+ Monocyte subset Was enriched  
in Patients with sle
Skewed monocyte subsets have been reported in several autoim-
mune inflammatory diseases such as rheumatoid arthritis (17). 
The distribution of monocytes was measured in a cohort of 62 
patients with SLE and 35 age-matched HCs to investigate whether 
this change also existed in SLE. The patients with SLE consisted of 
57 female and 5 male subjects, and the median disease duration 
was 60 months with a range of 3–432 months.
The frequencies of CD16+ monocyte subset were significantly 
elevated in patients with SLE than in healthy individuals (SLE: 
33.78  ±  16.19% vs. HC: 19.1  ±  7.49%, P  <  0.001). Patients 
with SLE exhibited a significantly higher percentage of NCM 
(SLE: 14.92 ±  12.51% vs. HC: 11.27 ±  4.83%, P <  0.05) and 
IM (SLE: 18.86 ± 9.44% vs. HC: 7.84 ± 5.09%, P < 0.001), with 
obviously reduced frequencies of CM (SLE: 64.96 ± 16.87% vs. 
HC: 78.72 ± 8.50%, P < 0.001) (Figure 2) when compared with 
control donors.
In patients with SLE, the frequencies of CD16+ monocytes 
were positively correlated with serum IgA concentrations 
(r = 0.267; P < 0.05) and anti-dsDNA antibody levels (r = 0.349; 
P < 0.01), which implicated that patients with elevated frequen-
cies of CD16+ monocytes would be at a high risk of Ig production 
or autoantibody development. On the contrary, the percentage 
of CD16− subsets was negatively correlated with serum IgA 
(r = −0.26; P < 0.05) and anti-dsDNA antibody levels (r = −0.345; 
P < 0.01). The frequencies of NCM subset were correlated with 
anti-dsDNA antibody levels (r  =  0.302; P  <  0.05), while the 
frequencies of IM subset were correlated with serum IgA levels 
(r = 0.287; P < 0.05). Other laboratory data, including IgG, IgM, 
C3 level, C4 level, AnuA, ESR, and 24-h proteinuria excretion, did 
not show significant correlation with monocyte subsets (Table 1). 
The frequencies of monocyte subsets were further compared 
between patients with and without particular antibodies, includ-
ing AnuA, anti-Sm Ab, anti-SSA Ab, and anti-SSB Ab. Detailed 
analysis of such autoantibodies in the patient cohort revealed no 
predictive factors for the expansion of CD16+ monocytes (Table 
S1 in Supplementary Material). The correlation analysis revealed 
slightly weak correlation between monocyte subsets and serum 
anti-dsDNA Abs or IgA levles, indicating that monocyte subset 
might contribute to B cell response in SLE.
TaBle 1 | correlations between each monocyte subset frequencies and clinical parameters in sle.
clinical parameters cD16+ subset (%) ncM (%) iM (%) cM (%)
spearman’s r P spearman’s r P spearman’s r P spearman’s r P
IgA 0.267* 0.038 0.012 0.925 0.287* 0.025 −0.26* 0.043
IgG 0.061 0.642 0.045 0.733 0.095 0.472 −0.055 0.678
IgM −0.095 0.472 −0.15 0.252 −0.1 0.466 0.09 0.494
C3 0.092 0.481 0.116 0.372 0.06 0.648 −0.071 0.584
C4 0.061 0.642 0.004 0.979 0.185 0.156 −0.031 0.816
Anti-dsDNA Ab 0.349** 0.006 0.302* 0.018 0.129 0.32 −0.345** 0.006
AnuA 0.079 0.533 0.093 0.484 0.055 0.682 −0.098 0.462
ESR −0.171 0.187 −0.091 0.484 −0.14 0.281 0.164 0.206
24-h proteinuria 0.059 0.681 −0.051 0.722 −0.228 0.107 0.188 0.187
*P < 0.05.
**P < 0.01.
SLE, systemic lupus erythematosus; Anti-dsDNA Ab, anti-double-strand DNA antibody; AnuA, anti-nucleosome antibody; C3, complement 3; C4, complement 4, ESR, erythrocyte 
sedimentation rate. Spearman’s correlation coefficient (r) was applied to detect correlation between two numerical data.
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cD16+ Monocytes in Patients with sle 
shared Different cell-surface Marker 
Profiles from cD16+ Monocytes in hcs
CD16+ monocytes from patients with SLE were characterized 
by lower expression of HLA-DR (P <  0.05) but higher CD163 
and CCR5 (P < 0.001) expression compared with the monocytes 
from control donors (P <  0.001) (Figures  3C–E; Table S2 in 
Supplementary Material). CD16− monocytes from patients with 
SLE also expressed less HLA-DR but more CD163 compared 
with those from HCs (P <  0.001) (Figures  3C,D; Table S2 in 
Supplementary Material). Specially, CX3CR1 expression on 
CD16− monocytes was elevated in patients with SLE (P < 0.01) 
(Figure 3F; Table S2 in Supplementary Material). No difference 
in CD80 and CD86 expression on both CD16+ monocytes and 
CD16− monocytes was detected between patients with SLE and 
HCs (Figures 3A,B; Table S2 in Supplementary Material). In SLE 
patients, CD16+ monocytes also shared different phenotypes from 
CD16− monocytes (Figure  3). CD163 is an anti-inflammatory 
marker, whereas HLA-DR is a proinflammatory marker. These 
data demonstrated the downregulation of proinflammatory sur-
face markers but the upregulation of anti-inflammatory markers 
in SLE, which was different from the presumptive results. This 
discrepancy might be due to a negative feedback existing to 
maintain monocyte homeostasis in SLE.
cD16+ Monocytes Perpetuated  
T-cell-Mediated inflammation in sle
Purified monocyte subsets with CD4+ T cells from the same 
donors were cultured in the presence of anti-CD3 and anti-CD28 
antibodies and M-CSF to evaluate the effects of CD16+ and 
CD16− monocytes on T-cell function. Anti-CD3 and anti-CD28 
antibodies were added for supporting T-cell activation, while 
M-CSF was added for monocyte survival maintenance.
CD16+ Monocytes Were More Functionally Effective 
on Promoting T-Cell Responses Compared with 
CD16− Monocytes in HCs
CD4+ T cells demonstrated stronger Th1 (IFN-γ+CD4+) and 
Th2 (IL-4+CD4+) cell responses in the presence of CD16+ 
monocytes (P < 0.05) (Figures 4A,B). CD4+ T cells cocultured 
with CD16− monocytes also contained higher numbers of Th1 
cells than did CD4+ T cells cultured alone (P < 0.05) (Figure 4A). 
Nevertheless, CD16− monocytes did not efficiently promote Th2 
activation in HCs (Figure 4B). No difference in the induction of 
Th17-cell activation was observed (Figure 4C). Compared with 
the CD16− subset, CD16+ monocytes had no effect on promoting 
Treg (Foxp3+ CD4+) differentiation in HCs (Figure 4D).
CD16+ Monocytes Enhanced Th17-Cell 
Differentiation in SLE
In patients with SLE, the differentiation of CD4+ T cells into Th1, 
Th2, and Th17 cells increased in the presence of either CD16+ or 
CD16− monocytes (Figures 4A–C). Specially, CD16+ monocytes 
induced more Th2 responses compared with CD16− monocytes 
in patients with SLE (P < 0.05) (Figure 4B). CD16+ and CD16− 
monocytes from SLE patients were both potent at promoting 
CD4+ T cells to differentiate into Treg cells, although CD4+ 
T  cells cocultured with CD16+ monocytes demonstrated weak 
effects on Treg responses than did CD4+ T cells cocultured with 
CD16− monocytes (P < 0.01) (Figure 4D).
The two monocyte subsets, particularly CD16+ monocytes, 
induced a significant increase in Th17 cells in patients with SLE 
compared with HCs (P < 0.05) (Figure 4C). However, no differ-
ence was found in the induction of Th1, Th2, and Treg cells by 
CD16+ monocytes and CD16− monocytes between patients with 
SLE and HCs, respectively (Figures 4A,B,D).
CD16+ Monocytes Induced T Cell Proinflammatory 
Cytokine Production in SLE
Next, whether CD16+ monocytes could influence the secre-
tion of IFN-γ and IL-17A by T cells was assessed. Both CD16+ 
monocytes from patients with SLE and HCs upregulated IFN-γ 
secretion. However, no difference was found in the secretion 
of IFN-γ induced by CD16+ monocytes and CD16− monocytes 
between patients with SLE and HCs, respectively (Figure 5A). The 
two monocyte subsets, particularly CD16+ monocytes, induced a 
significant increase in IL-17A secretion in patients with SLE com-
pared with HCs (Figure 5B), which was consistent with the flow 
cytometry data. Of note, the baseline concentrations of IFN- γ and 
FigUre 3 | cD16+ monocytes as well as cD16− monocytes from patients with sle and hcs shared different phenotypes regarding cell-surface 
markers, including cD80 (a), cD86 (B), hla-Dr (c), cD163 (D), ccr5 (e), and cX3cr1 (F). MFI, median fluorescence intensity. All samples were collected 
from fresh blood. Data were expressed as mean ± SD and analyzed by non-parametric paired t test and Mann–Whitney U test. *P < 0.05, **P < 0.01, ***P < 0.001; 
NS, no significance.
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IL-17A in HCs were higher than SLE, probably due to the in vitro 
operation-induced slight activation (collected from buffy coat).
CD16+ Monocytes Promoted T-Cell Proliferation  
in SLE
The percentage of CFSElowCD4+ T cells in T cells cocultured 
with CD16+ monocytes was significantly higher compared 
with those in T cells cocultured with CD16− monocytes or T 
cells cultured alone (P <  0.01 and P <  0.05), indicating that 
CD16+ monocytes were the predominant monocyte subset 
stimulating T-cell proliferation in HCs. Similarly, CD16+ 
monocytes from SLE patients also induced significant CD4+ 
T-cell proliferation (P < 0.05). Importantly, CD16− subset from 
patients with SLE also promoted CD4+ T-cell proliferation. 
AC
D
B
FigUre 4 | cD16+ monocytes promoted T-cell-mediated inflammation in sle. CD16+ or CD16− monocytes were cocultured with CD4+ T cells isolated from 
freshly collected SLE blood or blood bank collected HC blood buffy coat for 5 days in the presence of anti-CD3 (1 μg/mL) and anti-CD28 (1 μg/mL) antibodies and 
M-CSF (50 ng/mL). Intracellular IFN-γ, IL-4, and IL-17A expression was detected by flow cytometry after PMA (50 ng/mL), ionomycin (1 μg/mL), and BFA (10 μg/mL) 
stimulation for 5 h on day 5. The percentage of Treg (CD4+Foxp3+) was also analyzed. Representative pseudocolor dots depicted Th1 (a), Th2 (B), Th17 (c), and 
Treg (D) frequencies in CD4+ T cells after coculture with each monocyte subset from one patient and one control donor. The proportion of Th1, Th2, Th17, and Treg 
cells was calculated after coculture of CD4+ T cells with each monocyte. The percentage increases in T-cell subsets in cocultures of monocytes and T cells 
compared with CD4+ T cells cultured alone were compared between 7 healthy individuals and 10 patients with SLE. Data were expressed as mean ± SD and 
analyzed by non-parametric paired t test and Mann–Whitney U test. *P < 0.05, **P < 0.01; NS, no significance.
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FigUre 5 | cD16+ monocytes promoted T-cell-mediated cytokine secretion in sle. CD16+ or CD16− monocytes were cocultured with CD4+ T cells isolated 
from freshly collected SLE blood or blood bank collected HC blood buffy coat for 5 days in the presence of anti-CD3 (1 μg/mL) and anti-CD28 (1 μg/mL) antibodies 
and M-CSF (50 ng/mL). The concentrations of IFN-γ and IL-17A in the supernatants were measured by ELISA. IFN-γ (a) and Th17A (B) levels were compared 
between different groups in HCs and patients with SLE. Data were expressed as mean ± SD and analyzed by non-parametric paired t test and Mann–Whitney  
U test. *P < 0.05, **P < 0.01; NS, no significance.
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However, CD16+ monocyte subset was more efficient than 
CD16− subset at promoting CD4+ T-cell proliferation in SLE 
(P < 0.05) (Figures 6A,B). T-cell proliferation was enhanced 
when cocultured with both SLE monocyte subsets, particularly 
CD16+ monocytes, suggesting the potential proinflammatory 
phenotype of monocyte subsets in SLE when compared with 
HCs (Figure 6C).
cD16+ Monocyte subset exacerbated 
B-cell activation in sle
To test the effects of CD16+ and CD16− monocytes on B-cell 
activation, purified total B cells (CD19+) were cocultured with 
or without autologous monocyte subsets in the presence of anti-
CD40 antibody and M-CSF. Anti-CD40 antibody and M-CSF 
supported B-cell and monocyte survival, respectively. Then, 
the levels of IgG, IgA, and IgM were detected in the coculture 
supernatants to explore further whether each monocyte subset 
could impact the total antibody response.
CD16+ Monocytes Induced CD19+ B Cells to 
Differentiate into MBs and PBs but Inhibited the 
Generation of Breg Cells in HCs
CD16+ monocytes promoted CD19+ B cells to differentiate into 
MBs and PBs in HCs (Figures 7A,B). However, CD19+ B cells 
cocultured with CD16− monocytes did not exhibit significantly 
increased frequencies of MBs and PBs. Both CD16+ and CD16− 
subsets suppressed CD19+ B cells to differentiate into Breg cells 
(Figure 7C). CD19+ B cells demonstrated more Breg differentia-
tion inhibition, although not significant, in the presence of CD16+ 
monocytes compared with CD16− subset (Figure 7C).
Both PB Activation and Breg Differentiation Induced 
by CD16+ Monocytes Were Exacerbated in Patients 
with SLE
Both CD16+ and CD16− monocytes had no effects on MB 
responses (Figure  7A), while both monocyte subsets, particu-
larly CD16+ monocytes, were effective at inducing B cells to 
differentiate into PBs in SLE (Figure 7B). In SLE, both CD16+ 
and CD16− monocytes slightly promoted Breg differentiation 
(Figure 7C).
MB activation induced by CD16+ monocytes was sig-
nificantly attenuated in patients with SLE compared with HCs 
(P <  0.05), and MB activation induced by CD16− SLE subset 
was even inhibited (P <  0.05) (Figure  7A). In contrast, PB 
activation induced by CD16+ monocytes and CD16− subset 
was enhanced in SLE (Figure 7B). The phenomenon was also 
observed in Breg cell differentiation (Figure  7C). In patients 
with SLE, both CD16+ and CD16− subsets promoted Breg cell 
responses, which were different from the inhibitory roles of 
CD16+ and CD16− monocytes on Breg differentiation in HCs 
(Figure 7C).
AB C
FigUre 6 | cD16+ monocytes promoted T-cell proliferation in sle. CFSE-labeled CD4+ T cells isolated from freshly collected SLE blood or blood bank 
collected HC blood buffy coat were cocultured with CD16+ and CD16− monocytes for 60 h in the presence of anti-CD3 (1 μg/mL) and anti-CD 28 (1 μg/mL) 
antibodies and M-CSF (50 ng/mL). CFSE histograms depicted the number of events (y-axis) and the fluorescence intensity (x-axis), with proliferating cells displaying 
a progressive loss in fluorescence intensity following cell division, indicative of proliferating cells. (a) Representative histogram plots from a patient with SLE displayed 
the frequencies of CFSElow T cells in monocyte/T-cell cocultures and T cells cultured alone. (B) Percentages of CFSElow T cells in CD4+ T cells after coculture with 
each monocyte subset from five healthy donors and six patients with SLE. (c) The percentage increase in CFSElow T cells in cocultures of monocytes and T cells 
compared with CD4+ T cells cultured alone was compared between five healthy individuals and six patients with SLE. Data were expressed as mean ± SD and 
analyzed by non-parametric paired t test and Mann–Whitney U test. *P < 0.05, **P < 0.01; NS, no significance.
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CD16+ Monocytes Were More Effective in Stimulating 
B-Cell IgG Secretion in SLE
Both CD16+ monocytes and CD16− monocytes efficiently induced 
CD19+ B cells to secrete IgG and IgA in HCs. In particular, CD16+ 
subset was less efficient than CD16− monocytes at promoting IgA 
production. Both CD16+ and CD16− subsets had no effect on IgM 
response (Figure 8A).
Both CD16+ and CD16− monocytes were potent at inducing 
CD19+ B cells to produce IgG in SLE. CD19+ B cells cocultured 
with CD16+ monocytes from SLE patients secreted elevated 
levels of IgA. On the contrary, CD19+ B cells cocultured with 
CD16− monocytes exhibited increased production of IgM in 
SLE (Figure 8B). Compared with HCs, IgG responses induced 
by CD19+ B cells in the presence of CD16+ (P <  0.05) and 
CD16− (P  <  0.01) subsets were significantly exacerbated in 
patients with SLE. CD16− monocytes from patients with SLE 
induced less IgA secretion compared with CD16− monocytes 
from HCs (P < 0.05). No difference in IgM response induced by 
CD16+ and CD16− subsets between patients with SLE and HCs 
was observed (Figure 8C). Of note, the baseline concentrations 
of Ig levels in HCs were a bit higher than SLE, probably due to 
the in vitro operation-induced slight activation (collected from 
buffy coat).
DiscUssiOn
This study showed that an enrichment of CD16+ monocytes 
in the peripheral blood of patients with SLE is associated with 
serum autoantibody production and that CD16+ monocytes 
exhibited a proinflammatory phenotype with high CD80, CD86, 
HLA-DR, and CX3CR1 expression. In SLE, CD16+ monocyte 
subset induced both Th1/Th2 cell expansion and promoted Treg 
development and had an enhanced capacity to promote T-cell 
proliferation and differentiation into a Th17 phenotype. The 
study demonstrated for the first time that CD16+ monocytes from 
patients with SLE could efficiently drive B-cell responses, with 
AB
C
FigUre 7 | cD16+ monocyte subset exacerbated B-cell activation in sle. SLE CD16+ monocytes had an enhanced capacity on PB and Breg 
differentiation but attenuated MB development. Monocyte subsets were cocultured with CD19+ B cells isolated from freshly collected SLE blood or blood 
bank collected HC blood buffy coat for 3 days in the presence anti-CD40 antibody (3 μg/mL) and M-CSF (50 ng/mL). The expression of CD20 and CD27 as 
well as CD24 was assessed. (a) Representative histogram plots from HCs and patients with SLE displayed the frequencies of MB (CD27+CD19+) cells in 
monocyte/B-cell cocultures. Graphs showed the cumulative MB frequencies in cocultures of monocytes/B cells and CD19+ B cells cultured alone from eight 
healthy individuals and seven patients with SLE. The difference in the percentage increase in MB cells in cocultures of monocytes and B cells compared with 
CD19+ B cells cultured alone was compared between HCs and SLEs. (B) Representative dot plots from HCs and patients with SLE demonstrated the 
frequencies of PB (CD20−CD27+CD19+) cells in monocyte/B-cell cocultures. Graphs showed the cumulative frequencies of PBs in cocultures of 
monocytes/B cells and CD19+ B cells cultured alone from eight healthy individuals and seven patients. Percentage increase in PBs in cocultures of monocytes 
and B cells compared with CD19+ B cells cultured alone was identified between HCs and patients with SLE. (c) Representative contour plots from HCs and 
patients with SLE showed the frequencies of Breg (CD24+CD27+CD19+) cells in monocyte/B-cell cocultures. Graphs displayed the cumulative frequency of 
Bregs in cocultures of monocytes/B cells and CD19+ B cells cultured alone from eight healthy individuals and five patients with SLE. Percentage increase in 
Bregs in cocultures of monocytes and B cells compared with CD19+ B cells cultured alone was compared between HCs and patients with SLE. MBs, memory 
B cells; PBs, plasma B cells; Bregs, regulatory B cells. Data were expressed as mean ± SD and analyzed by non-parametric paired t test and Mann–Whitney 
U test. *P < 0.05, **P < 0.01; NS, no significance.
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AB
C
FigUre 8 | cD16+ monocytes were more effective in stimulating B-cell igg secretion in patients with sle. CD16+ or CD16− monocytes were cocultured 
with CD19+ B cells isolated from freshly collected SLE blood or blood bank collected HC blood buffy coat for 3 days in the presence of anti-CD40 antibody (3 μg/
mL) and M-CSF (50 ng/mL). The total Ig was assayed by ELISA. (a) Bar graphs showed the Ig (IgG, IgA, and IgM) levels in the supernatant of monocyte/B-cell 
cocultures and CD19+ B cells cultured alone from eight healthy individuals. (B) Bar graphs demonstrated the Ig (IgG, IgA, and IgM) levels in the supernatant of 
monocyte/B-cell cocultures and CD19+ B cells cultured alone from 10 patients with SLE. (c) The Ig increase in cocultures of monocytes and B cells compared with 
CD19+ B cells cultured alone was compared between eight healthy individuals and 10 patients with SLE. Data were expressed as mean ± SD and analyzed by 
non-parametric paired t test and Mann–Whitney U test. *P < 0.05, **P < 0.01; NS, no significance.
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exacerbated impacts on PB and Breg differentiation as well as IgG 
production but attenuated effects on the generation of MB cells.
This study showed that the frequencies of CD16+ subset 
increased, while CD16− monocytes decreased in patients with 
SLE. Further analysis showed that the proportions of non-clas-
sical and IM were higher in SLE than their healthy counterparts, 
which was consistent with the findings of Mukherjee (21). This 
observation was also consistent with the data showing that CD16+ 
monocyte subsets are enriched in some autoimmune diseases 
and may be involved in the induction of inflammatory immune 
response (38–41). The possible explanation of monocyte altera-
tion is that the in vivo cytokine and hormone environments in 
SLE may lead to the conversion of CD16− monocytes into CD16+ 
monocytes (20). It was shown that CD16+ monocytes were the 
producers of proinflammatory cytokines, including TNFα, 
IL-1, and IL-6 (13–16, 42). Mikołajczyk et  al. demonstrated 
that CD14dimCD16+ monocytes might be an important sub-
population of proinflammatory monocytes related to increased 
development of atherosclerosis in SLE (22). The elevated sur-
face expression of CD80, CD86, HLA-DR, and CX3CR1 (43) 
on CD16+ monocytes further indicated their involvement in 
inflammatory immune response. The chemokine receptor CCR5 
plays an important role in recruiting these cells into inflamed 
organs and consumes its own ligands to restrain local chemokine 
levels, thereby limiting inflammatory cell influx (44). The CCR5 
downregulation on CD16+ intermediate and non-classical 
subsets may explain their anti-inflammatory features during the 
disease course. Both CD16+ subsets and CD16− monocytes from 
SLE patients exhibited a widely changes on cell-surface marker 
expression, which may be explained by immunosuppressive 
therapy in patients with SLE (45), but it remains unknown 
whether treatment with SLE agents can change the monocyte 
phenotypes and further study was necessary for reasonable 
explanation in the future.
Disturbed T-cell signaling and Th17/Treg imbalance are 
documented to play an important role in developing SLE 
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and could be responsible for an increased proinflammatory 
response, especially in the active form of the disease (4, 46, 47). 
Human monocytes are well known to influence CD4+ cells to 
differentiate into discrete Th cell subsets. The results presented 
in this work investigated the effects of each monocyte subset on 
the control of Th and Treg development in patients with SLE 
and their healthy counterparts. In contrast to CD16− mono-
cytes, CD16+ subset significantly promoted the expansion of 
IL-4-producing T cells in HCs. Also, CD16+ monocyte subset 
had no effects on Treg induction, supporting its defective 
inflammation regulatory roles. CD16+ subset seemed to be 
equivalent to CD16− subset at inducing the activation of 
IFN-γ-producing T cells. Interestingly, Th17 cell development 
was not influenced by both CD16+ inflammatory monocytes 
and classical CD16− monocytes in HCs. These data suggested 
the predominant role of circulating CD16+ monocyte subset 
in controlling the balance in Th-polarized immune response. 
CD16+ blood monocytes as well as CD16− subsets can modu-
late Th1, Th2, and Treg development in patients with SLE. The 
critical finding of the present study was the identification of 
each monocyte subset that could modulate Th17 expansion in 
patients with SLE, to a lesser extent, than in HCs. In recent 
years, IL-17-producing CD4+ T cells have emerged as a major 
pathogenic T-cell population that is present at increased fre-
quencies in SLE and that correlates with disease severity (47). 
Recovery of the immune balance between Th17 and regulatory 
T cells may serve as a treatment for SLE (48). The underlying 
mechanisms of this expansion of the Th17-cell population are 
not fully understood, but the present results demonstrated that 
SLE monocyte subsets were able to drive remarkable Th17-cell 
expansion in vitro, indicating a central role of abnormal mono-
cyte distribution in this process.
Autoantibodies are a hallmark of SLE, and B-cell deletion 
remains one of the main effective therapies in this disease (49). 
The present study demonstrated for the first time that both CD16+ 
and CD16− monocytes from patients with SLE exhibited exacer-
bated capacity for B-cell response, leading to abnormal antibody 
secretion. In particular, CD16+ and CD16− monocytes from 
patients with SLE could efficiently induce more PBs compared 
with CD16+ and CD16− monocyte subset from HCs. Although 
HC monocytes were able to induce IgG secretion, CD16+, and 
CD16− monocytes from patients with SLE were more efficient 
than the corresponding HC monocyte subsets at inducing IgG 
response. The present results also indicated that the expansion of 
CD16+ monocytes was positively correlated with autoantibody 
production in patients with SLE, which further confirmed that 
abnormal monocyte subset was responsible for aberrant B-cell 
activation. All these suggested that a potential heightened activa-
tion state of each monocyte subset in SLE might result in skewed 
B-cell responses, leading to augment autoantibody production, 
which was consistent with the finding that B cells were overac-
tivated in SLE (1, 50, 51). Specially, MB activation induced by 
CD16+ monocytes was significantly attenuated, and MB dif-
ferentiation induced by CD16− monocytes was even inhibited in 
patients with SLE. The underlying mechanism of this discrepancy 
need to be further studied.
In summary, the present study demonstrated the expansion of 
pathogenic CD16+ monocytes in SLE, revealing their important 
roles in stimulating Th cell subsets and the differentiation of 
B-cell response in diseased condition. These data highlighted the 
importance of the innate immune system in eliciting pathogenic 
T- and B-cell responses in SLE and suggested that specific mono-
cyte subsets might be critical targets to control the inflammation.
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